Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T18:48:16.528Z Has data issue: false hasContentIssue false

P0055 - Prolactin inhibition by SSRI`S

Published online by Cambridge University Press:  16 April 2020

L. Timmerman
Affiliation:
Psychiatry Department, Twenteborg Ziekenhuis, Almelo, The Netherlands
A.M. Wessels
Affiliation:
Psychiatry Department, Twenteborg Ziekenhuis, Almelo, The Netherlands

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The relationship between selective serotonin reuptake inhibitors(SSRI`S) is presented.

The SSRI dependent side effects are mostly characterized by serotonin potentiation.

Both SSRI`S and tricyclic antidepressants can also cause extrapyramidal side effects.

The occurence of movement disorders such as akathisia, dystonia and Parkinsonism after use of SSRI`S was reported.

Furthermore descriptions of deterioration of Parkinson`s disease after use of fluoxetine, fluvoxamine and paroxetine can be found in the literature.

Medication having a serotonergic effect can cause a prolactin level elevation through an indirect mechanism.

Prolactine elevation may cause galactorrhea.

Two mechanism are considered to explain the prolactin release induced by the serotonergic system: the presynaptic inhibition of dopamine discharge by the serotonergic receptors or the direct stimulation of the hypothalamic postsynaptic receptors.

Type
Poster Session II: Antidepressants
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.